Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus

Background and purpose: Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospe...

Descripción completa

Detalles Bibliográficos
Autores: Zilli, Thomas, Achard, Vérane, Dal Pra, Alan, Schmidt-Hegemann, Nina, Jereczek-Fossa, Barbara Alicja, Lancia, Andrea, Ingrosso, Gianluca, Alongi, Filippo, Aluwini, Shafak, Arcangeli, Stefano, Blanchard, Pierre, Conde Moreno, Antonio, Couñago, Felipe, Créhange, Gilles, Dirix, Piet, Gómez de Iturriaga Piña, Alfonso, Guckenberger, Matthias, Pasquier, David, Sargos, Paul, Scorsetti, Marta, Belka, Claus
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad del País Vasco
Repositorio:Addi. Archivo Digital para la Docencia y la Investigación
OAI Identifier:oai:addi.ehu.eus:10810/58843
Acceso en línea:http://hdl.handle.net/10810/58843
Access Level:acceso abierto
Palabra clave:prostate cancer
radiotherapy
SBRT
elective nodal radiotherapy
oligometastases
ESTRO-ACROP
Descripción
Sumario:Background and purpose: Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far. Despite the lack of strong level I evidence, metastasis-directed therapies (MDT) are widely used in clinical practice, mainly based on retrospective and small phase 2 studies and with a large difference across centers. Pending results of ongoing prospec-tive randomized trials, there is a clear need for more consistent treatment indications and radiotherapy practices.Material and methods: A European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee consisting of radiation oncologists' experts in prostate cancer was asked to answer a dedicated question-naire, including 41 questions on the main controversial issues with regard to oligometastatic prostate cancer.Results: The panel achieved consensus on patient selection and routine use of prostate-specific mem-brane antigen positron emission tomography (PSMA PET) imaging as preferred staging and restaging imaging. MDT strategies are recommended in the de novo oligometastatic, oligorecurrent and oligopro-gressive disease setting for nodal, bone and visceral metastases. Radiation therapy doses, volumes and techniques were discussed and commented.Conclusion: These recommendations have the purpose of providing standardization and consensus to optimize the radiotherapy treatment of oligometastatic prostate cancer until mature results of random-ized trials are available.

Similares en LA Referencia